Cancer survival by age visualisation
For many different cancers, this data visualisation provides cancer survival data by age, age adjusted survival rates and changes in the age characteristics of people diagnosed. Help with terms, and information about the data, is available by placing the mouse pointer over the icons found near the top of the page. Additional guidance about using this data is located in the data commentary 6 About age adjusted survival.
Cancer relative and observed survival by age data visualisation
This cancer survival visualisation contains three figures. The visualisation presents statistics for the selected cancer and provides statistics by sex.
Figure 1 is a line graph that contains time series information on 1 to 5-year observed or relative survival rates for the selected cancer in 5-year periods for selected age groups (0–19, 20–39, 40–59, 60–79, 80+) and all ages.
Figure 2 is a line graph that contains information on 1 to 5-year observed or relative age-adjusted survival rates for the selected cancer in 5-year periods. Age-adjusted rates are shown for backward-looking and forward-looking adjustments. Please read Cancer data commentary C6 for more information about age-adjusted survival and the backward-looking and forward-looking survival data.
Figure 3 is a stacked bar chart that contains the number of cases diagnosed for the selected cancer from 1982 to the most recent year available for reporting, at the time of release, for the age groups: 0–19, 20–39, 40–59, 60–79, 80+. The chart can be shown as the number of cases diagnosed or as a percentage for each age group of the total cases diagnosed.
The visualisation includes information about many different cancers and the statistics within this visualisation are available in Excel format within the Data section of this report.
Cancer survival by age data are available as supplementary tables.
AIHW (Australian Institute of Health and Welfare) 2019. BreastScreen Australia monitoring report 2018. Cancer series no.127. Cat no. CAN 128. Canberra: AIHW
Al-Marhoon M, Osman A, Kamal M and Shokier A 2011. Incidental vs symptomatic renal tumours: Survival outcomes. Arab Journal of Urology 9(1): 17–21.
Luke C, Tracey E, Stapleton A and Roder D 2010. Exploring contrary trends in bladder cancer incidence, mortality and survival: implications for cancer research and cancer control. Internal Medicine Journal 40:357–62.
Qaseem A, Usman N, Jayaraj J S, et al. (September 02, 2019) Cancer of Unknown Primary: A Review on Clinical Guidelines in the Development and Targeted Management of Patients with the Unknown Primary Site. Cureus 11(9): e5552. doi:10.7759/cureus.5552
Smith D Supramaniam R, Marshall V and Armstrong B 2008. Prostate cancer and prostate specific antigen testing in New South Wales. Medical Journal of Australia 189(6): 315–18.
Vaccarella S, Franceschi S, Bray F, Wild C, Plummer M and Dal Maso L 2016. The increase in thyroid cancer may be due to an increase in medical surveillance and the introduction of new diagnostic techniques, such as neck ultrasonography. The New England Journal of Medicine 375: 614–17.
Victorian Cancer Registry 2023. Cancer in Victoria, 2022. Cancer Council Victoria, accessed 29 July 2024.
Wyld D, Wan M, Moore J, Dunn N and Youl P 2019. Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia. Cancer Epidemiology, Volume 63, 101598, ISSN 1877–7821.